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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both), along with
any possible adverse effects.
B A C K G R O U N D
Description of the condition
Please refer to the glossary for the explanation of clinical terms
(Appendix 1).
Sickle cell disease (SCD) encompasses a host of genetically inher-
ited disorders in which red blood cells become increasingly de-
formed and friable, causing vaso-occlusion and haemolysis. This
disease is one of the most common, severe, single gene mutation
(monogenic) disorders (Weatherall 2001).
The disease is most prevalent in sub-Saharan Africa, affecting an
estimated 230,000 children born regionally every year - account-
ing for 80% of the total global incidence (David 2010). In the
USA, it affects around 100,000 people, predominantly those of
African descent. The disease occurs in about one in every 500
African-American births and one in every 1000 to 1400 Hispanic-
American births. Approximately two million Americans, or one
in 12 African Americans, carry the sickle cell allele (WHO 2015).
This geographical predominance corresponds to an adaptive ad-
vantage: heterozygous carriers (sickle cell trait) are naturally resis-
tant to infection by the endemic Plasmodium falciparum (P falci-
parum) malarial parasite (Barbedo 1974).
The vaso-occlusive crisis (VOC) is the hallmark of the disease
and is often unpredictable, varies in quality, duration, location
and severity, and can be precipitated by known and unknown
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factors (Ballas 2005). Vaso-occlusive pain episodes are the most
common cause of recurrent morbidity, hospital admissions and
work or school absenteeism in people with SCD (Platt 1991).
Approximately 90% of hospital admissions of people with SCD
are for treating acute pain (Brozovic 1987).Hypoxia, dehydration,
acidosis, cold exposure and strenuous exercise also can lead to
sickling of red blood cells leading to an acute painful episode.
Nociceptive sickle cell pain may be acute recurrent painful crises,
chronic pain syndromes and neuropathic pain. The acute painful
crisis evolves through prodromal, initial, established and resolv-
ing phases (Ballas 2012). Chronic sickle cell pain may be due to
avascular necrosis and leg ulcers or intractable pain without any
obvious signs. Chronic pain is usually associated with emotional
distress, behavioural dysfunction, family stress, financial concern,
frequent visits to healthcare providers, heavy use of analgesic med-
ications and fear (Ballas 2005).
Treatment aims for SCD are to relieve pain, prevent infections and
manage complications (Stinson 2003). Despite being the main
source of discomfort for people with SCD, therapies for pain
crises are not definitive. Pharmacotherapies involve opioids, non-
opioids and adjuvants. Non-opioids (e.g. acetaminophen, nons-
teroidal anti-inflammatory drugs (NSAIDs) tramadol and corti-
costeroids) have a ’ceiling effect’ beyond which they are no longer
effective, and NSAIDs and corticosteroids have well-known com-
plications such as haemostasis, acute renal failure, congestive heart
failure when overused (Niscola 2009). Thus opioids are frequently
employed, as they have fewer systemic effects. However, their use
is plagued with reports of addiction, tolerance and drug-seeking
behaviour (Neville 2011). Moreover, opioids may contribute to
the development of acute chest syndrome during an acute sickle
cell pain crisis (Buchanan 2005).
These factors have motivated clinicians and researchers worldwide
to embrace a multidisciplinary approach towards pain manage-
ment in people with SCD, with a focus on including non-phar-
macological interventions. According to the recommendations of
the American Pain Society, pharmacological treatments for SCD
should be complimented by psychological, behavioral, and phys-
ical modalities (American Pain Society Guidelines 1999).
Description of the intervention
As defined by the American Physical Therapy Association, TENS
is the application of electrical stimulation to the skin for pain con-
trol. It is non-invasive, inexpensive, safe, and easy to use; a small
battery-powered device applies an electric current via two or more
non-invasive skin electrodes to stimulate underlying nerves and
thus reduce pain perception. It can be applied with different fre-
quencies, varying from low (< 10 Hz) to high (> 50 Hz). Intensity
can also vary with low-intensity stimulation producing a sensation
alone, while high-intensity stimulation triggers muscle contrac-
tion, and hence movement. Low-frequency TENS is usually given
at high-intensity (producing motor contraction and sensation),
while high-frequency TENS is given at lower intensities (produc-
ing both sensation and muscle contraction) (DeSantana 2008).
Conventional TENS has a high-stimulation frequency (40 Hz to
150 Hz) and low intensity between 10 mA to 30 mA. The pulse
duration is short (up to 50 microseconds). The onset of analgesia
with this setup is virtually immediate. Pain relief lasts while the
stimulus is turned on, but it usually abates when the stimulation
stops. In acupuncture like settings, the TENS unit delivers low
frequency stimulus trains at 1 Hz to 10 Hz, at a high stimulus in-
tensity, close to the tolerance limit of the individual. This method
is uncomfortable and is often considered for those who do not
respond to conventional TENS. Pulsed (burst) TENS uses low-
intensity stimuli firing in high-frequency bursts, but does not have
any added advantage over the conventional method.
Over the last 40 years, TENS has been evaluated for the man-
agement of pain in numerous conditions, including fibromyal-
gia (Sunshine 1996) rheumatoid arthritis, osteoarthritis, post-cae-
sarean pain, lower back pain (Milne 2004) neck pain and numer-
ous other causes. While reviews report that evidence on the effi-
cacy of TENS is inconclusive, magnetic resonance imaging (MRI)
studies implicate central pain signal modulation indicating a cen-
tral action (Kocyigit 2012). There are contraindications for the use
of TENS. These include use during pregnancy, as it may induce
premature labour, as well as application over the carotid sinuses,
due to the risk of acute hypotension through a vasovagal reflex. In
addition to these, it should not be placed over the anterior neck,
because laryngospasm due to laryngeal muscle contraction may
occur, the electrodes should not be placed in an area of sensory
impairment, where the possibility of burns exists and a TENS unit
should be used cautiously in individuals with a spinal cord stim-
ulator or an intrathecal pump.
How the intervention might work
A variety of mechanisms for the analgesic action of TENS have
been suggested, includingpresynaptic inhibition in the dorsal horn
of the spinal cord, endogenous pain control via endorphins, and
direct inhibition of nerve excitation and restoration of afferent
input (Kaye 2015). This produces a host of responses, includ-
ing sensation, movement (muscle contraction), and pain relief. In
people with SCD, vaso-occlusion leads to secondary tissue injury
which generates several major pain mediators like interleukin-1,
bradykinin which in turn sensitize peripheral nerve endings and
facilitate the transmission of painful stimuli along A-δ and C fibres
that reach the cerebral cortex via the spinal cord and the thalamus
(Ballas 2005). This partly corresponds to the ’gate control the-
ory’ (Melzack 1965) for the mechanism of analgesia produced by
TENS where the ’open gate’ between C fibres and T cells which
allow pain transmission centrally is closed by the electrical stimu-
lation to the skin provided by the TENS instrument.
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Why it is important to do this review
Over recent years, although considerable knowledge has been
gained on the pathophysiological mechanisms of pain and the
pharmacogenetics of analgesics (including opioids) there has been
not much progress in the clinical management of sickle cell pain.
Many adults with SCD still face accusations, assumptions and dis-
belief about their painful condition which is often wrongly per-
ceived by some healthcare providers as drug-seeking behaviour
(Ballas 2014). Mismanagement of pain in SCD may lead to se-
rious psychosocial and physiological consequences, such as de-
pression, low self esteem, anxiety and reduced participation in so-
cial activities, resulting in chronic pain interspersed with episodes
of acute exacerbations (Smith 2005). Hence, organizations such
as the American Pain Society recommended that pharmacologic
treatment for SCD should be complemented by complementary
and alternative medicine.
Cochrane Reviews on TENS for specific chronic pain condi-
tions have suggested that TENS is more effective than placebo
TENS, although methodological weaknesses in randomised con-
trolled trials (RCTs) have sometimes hindered definitive conclu-
sions (Bennett 2011; Brosseau 2003; Johnson 2010; Rutjes 2009).
Studies carried out on the effect of TENS on neck pain suggested
that active TENS may be more effective than placebo TENS
(Kroeling 2013). A systematic review on the effect of TENS on
cancer pain in adults suggested bone pain on movement may im-
prove in a cancer population on application of TENS, but most
of the results remained inconclusive due to a limited number of
RCTs included in the review (Hurlow 2012).
Most reviews of TENS therapy are inconclusive at present, which
is why a standardised, rigorous search and a Cochrane Review are
required in this disease area. This issue is further compounded
by the practical need to manage the acute pain crises, as well as
chronic pain conditions, experienced by millions of people with
SCD worldwide. Current pharmacological therapies produce too
many unacceptable side effects, and as already stated, recommen-
dations encourage the use of non-pharmacological methods in
SCD pain management. A Cochrane Review of the current ev-
idence regarding the effectiveness of TENS as a complementary
therapy for managing pain in people with SCD will allow health
professionals and researchers make informed decisions about the
use of this treatment.
O B J E C T I V E S
To assess the effects of TENS for managing pain in people with
SCD who experience pain crises or chronic pain (or both), along
with any possible adverse effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs. Quasi-RCTs will also be included if sufficient evidence is
provided to demonstrate that the treatment and control groups
are similar at baseline.
In reference to cross-over trials, as we are currently unaware of
the long-term effects of these interventions, we are unable to de-
termine whether the effects of the first intervention will interfere
with those of the second. In order to avoid introducing this bias
into the analysis, we will include only first-arm data from cross-
over trials, when available.
Types of participants
People with known SCD (SS, SC, Sβ and Sβ , proven by
electrophoresis and sickle solubility test, with family studies or
DNA tests as appropriate) of all ages and both sexes, in any setting.
Types of interventions
Wewill include all standardmodes ofTENSwhich includes bipha-
sic or monophasic electrical current delivered in pulses in high
frequency, low intensity or low frequency, high intensity or other
standard modes that produce perceptible sensation at the area of
application. Wewill exclude other modes of electrotherapy,TENS
that was delivered in intensities that were barely perceptible.
Eligible comparisons are:
• TENS with conventional treatment (e.g. analgesics) versus
conventional treatment alone;
• TENS versus placebo (sham) TENS;
• TENS versus other non-pharmacological modalities for
treatment of pain.
We do not plan to compare different intensities and frequencies of
TENS as all standard modes of TENS which produce perceptible
sensation at the area of application will be included in this review.
Placebo (sham) TENS devices may look exactly similar to active
TENS devices, but are deactivated and produce no current or may
produce a brief period of stimulation at the beginning which fades
out later. Due to the lack of perceptible stimulation in SHAM
TENS, blinding of participants to themode of treatment is almost
impossible (Sluka 2013) and this represents a risk of bias to all
sham-controlled trials of TENS (Gibson 2015).
Types of outcome measures
Primary outcomes
1. Pain relief ∗
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2. Pain intensity (as assessed by visual analogue pain scale
score (VAS) or other validated assessment tools for measuring
pain intensity during the use of TENS)
3. Frequency of pain episodes
* We aim to present data at two to four weeks and after four
weeks post intervention. For long-term usage (e.g. for a period of
one month) we will consider the outcome measures up to three
months. We will consider pain relief as moderate (at least 30%
pain relief over baseline) or substantial (at least 50%pain relief over
baseline) as defined by IMMPACT guidelines (Dworkin 2008).
Secondary outcomes
1. Changes in consumption of analgesic and opioids during
pain episodes
2. Changes in quality of life (QoL) (as measured by a validated
scale)
3. Ability to cope with the activities of daily living (ADL)
4. Adverse effects of the intervention
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
Relevant studies will be identified from the Cystic Fibrosis and
Genetic Disorders Group’s Haemoglobinopathies Trials Regis-
ter, using the search terms: (sickle cell OR (haemoglobinopathies
AND general)) AND transcutaneous electrical nerve stimulation
[TENS].
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of theCochraneCentral Register of ControlledTri-
als (CENTRAL) (updated each new issue of theCochrane Library)
and weekly searches of MEDLINE. Unpublished work is iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the Caribbean Health Research
Council Meetings; and the National Sickle Cell Disease Program
Annual Meeting. For full details of all searching activities for the
register, please see the relevant section of the Cochrane Cystic Fi-
brosis and Genetic Disorders Group’s website.
We will search the following databases (Appendix 2):
• Embase (Ovid, 1974 onwards);
• PubMed (https://www.ncbi.nlm.nih.gov/pubmed, 1946
onwards).
In addition, we will search the following trial registries and other
resources (Appendix 2):
• US National Institutes of Health Ongoing Trials Register,
ClinicalTrials.gov (https://clinicaltrials.gov/);
• WHO ICTRP register (http://apps.who.int/trialsearch/);
• ISRCTN (http://www.isrctn.com/);
• Google Scholar (https://scholar.google.co.uk/).
Regarding our use of Google Scholar, we will perform a Google
Scholar Advanced search, sort the results based on relevance, and
screen the first 100 search results for relevant studies.
Searching other resources
For assistance in identifying ongoing or unpublished studies, we
will contact study authors who have conducted prominent re-
search in the relevant field regarding their ongoing studies or other
relevant papers which may be eligible for inclusion.
Wewill search research paperswhich cannot be directly included in
this review (observational studies, systematic andnarrative reviews,
conference reports, etc.) for the citations of relevant studies which
can be included. These papers will then be sought and assessed for
possible inclusion.
Organisations that we will attempt to contact to request sugges-
tions for studies are:
• NCCIH formerly known as NCCAM;
• Foundation for Alternative and Integrative Medicine;
• American Alternative Medical Association;
• The Complementary and Natural Healthcare council;
• International Alternative Medical Association;
• The Association for Applied Psychophysiology and
Biofeedback (formerly the Biofeedback Society of America).
Regarding grey literature, studies have shown that published stud-
ies often overestimate outcomes, compared to grey literature arti-
cles (Hopewell 2007). Moreover, exclusion of grey literature can
result in systematic error, thus seriously threatening the validity of
a systematic review (McAuley 2000). Therefore, to avoid this risk
of publication bias, we will search grey literature databases in our
attempt to identify relevant studies and authors from conference
proceedings. We propose to search the following databases (rec-
ommended in the Cochrane Handbook For Systematic Reviews of
Interventions) for unpublished reports or articles which may be ap-
propriate for inclusion in this systematic review (Higgins 2011a):
• OpenGrey (www.opengrey.eu/);
• PsychEXTRA (www.apa.org/psycextra/);
• The Grey Literature Report (http://greylit.org/);
• The Agency for Healthcare Research and Quality (
www.ahrq.gov/);
• MedNar (http://mednar.com/mednar/desktop/en/
search.html).
Data collection and analysis
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Selection of studies
Two review authors (SP, MG) will independently assess the eli-
gibility of the trials identified by the literature searches by com-
pleting a trial selection form that will be designed in accordance
with the inclusion criteria. Each author will independently evalu-
ate each title for inclusion. If we do not find the relevant informa-
tion in the abstract, we will retrieve the relevant full text report(s),
if published, in order to complete this task. The authors will select
the trials approved by both authors for inclusion in the review. In
the case of any discrepancies relating to eligibility, a third author
(SKB) will arbitrate. We will tabulate the excluded trials under
’Characteristics of excluded studies’ and reasons will be given for
the exclusion. The review authors will be unmasked to the trial
authors, institutions and trial results during their assessments. We
will produce a PRISMA chart as a systematic illustration of the
entire trial selection process.
Data extraction and management
Two review authors (SP, SM) will independently and simultane-
ously extract data from the selected articles and this will be ver-
ified by two or three review authors with an aim to resolve any
disagreements by discussion and consensus.
We will extract data using a standardised, pre-tested data extrac-
tion form. We will design the data extraction form through a col-
laboration of the review authors, and then pilot test this using a
sample RCT and a quasi-RCT to ensure practical functionality.
We will extract the following information from the included stud-
ies.
1. Trial characteristics and source
• Trial identifier (ID) - to be created by the review author
• Report ID - to be created by the review author
• Citation
• Contact details
2. Methodology
• Trial design
• Trial time and duration
• Setting
• Randomisation
• Allocation sequence concealment
• Type of blinding used
• Concerns about bias
• Intention-to-treat analysis
3. Participants
• Total number
• Eligibility criteria
• Age and gender of participants
4. Interventions (TENS and variants)
• Total number of intervention groups
For each intervention and comparison group of interest
• Electrode position
• Professional discipline of the clinician delivering TENS
• Frequency and intensity of the electrical current applied
through the TENS device
• Frequency of administration
• Duration of administration
• Co-intervention(s)
5. Outcome measures
For each outcome of interest
• Outcome definition
• Units of measurement (if relevant)
• For scales, state upper and lower limits, and the
interpretation of the scale
6. Results
• Number of participants allocated to each intervention
group
For each outcome of interest
• Sample size
• Missing participants
• Summary data for each intervention group (mean and
standard deviation for continuous data, 2 x 2 contingency table
for dichotomous data, etc.)
Assessment of risk of bias in included studies
Two review authors (RD, SM) will independently assess the risk of
bias of the included studies by using the criteria outlined in chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b).
Each study will be assessed according to the following five com-
ponents.
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Masking (blinding) of participants and personnel
(performance bias), and masking of outcome assessment
4. Incomplete outcome data (attrition bias) through
withdrawals, dropouts and protocol deviations; and
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5. Selective reporting bias
We will also assess for any other sources of bias as reported in
theCochrane Handbook for Systematic Reviews of Interventions (bias
related to the specific study design, early or abrupt end of studies,
fraudulent studies) (Higgins 2011b). For each of the mentioned
components, we will assign judgements of either low, unclear or
high risk of bias.
We will record the results in the standard table provided in the
Review Manager software (RevMan 2014), and will summarize
the findings in a ’Risk of bias’ table or graph.We aim to resolve any
concerns or issues by discussion with a third review author (ALA).
We will address the implications of the ’Risk of bias’ assessment
in the discussion section.
Measures of treatment effect
We will analyse and present dichotomous data, such as need for
daily analgesic consumption between pain events, and ability to
cope with ADL using the risk ratios (RR) with 95% confidence
intervals (CIs). We will report adverse effects of the intervention
with 99% CI to avoid errors due to multiple statistical testing.
We will analyse and present continuous data, such as dose of anal-
gesic consumption between pain events, pain relief and pain in-
tensity as assessed by visual analogue pain scale score (on a scale of
0 to 10), improvements in quality of life (QoL), using the mean
differences (MD) (if outcomes are measured using the same scales)
along with their 95% CIs. If outcomes are measured using dif-
ferent scales, we will use the standardised MD (SMD) and corre-
sponding 95% CIs.
We will analyse and present count data, such as frequency of pain
episodes using the MD, which they will calculate by comparing
the difference in the mean number of events in the intervention
group as compared to the control group. If they are rare events,
we will present the results using the rate ratio with 95% CIs.
Where meta analysis is not possible, we will present a narrative
summary along with tabulated data.
Unit of analysis issues
The unit of analysis in this review will be the individual with
SCD. Results of any identified cluster-randomised studies will be
reported separately.
Regarding cross-over trials, aswe are currently unaware of the long-
term effects of these interventions, we are unable to determine
whether the effects of the first interventionwill interfere with those
of the second. In order to avoid introducing this bias into the
analysis, we will include only first-arm data from cross-over trials,
when available.
If we identify trials with multiple treatment arms, we will only
include those treatment arms whose parameters are minimally dif-
ferent from other included trials.
Dealing with missing data
We will contact trial authors to request access to the missing data
regarding methods, participants, interventions and outcomes. In
cases of missing data due to participant drop out we will conduct
a primary analysis based on participants for whom complete data
are available, provided that the total number of randomised par-
ticipants and the number of dropouts to follow-up are well docu-
mented. We assume that missing outcomes will not be a problem
if loss-to-follow-up is well documented, and is unrelated to out-
comes in both trial arms, as per chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). How-
ever, if the reasons for why the data are missing are not available,
we will document the possible effects of the missing participants
through a sensitivity analysis.
Assessment of heterogeneity
In order to deal with clinical heterogeneity, studies that examine
similar interventions will be pooled together.We will perform sep-
arate analyses for TENS compared to conventional treatment and
TENS compared to placebo TENS or other non-pharmacological
treatment. If we identify substantial (or higher) heterogeneity, and
provided there are sufficient data, thenwewill undertake subgroup
analyses according to the pre-planned comparisons described in
the section ’Subgroup analysis and investigation of heterogeneity’.
We will use the Chi² test for assessing heterogeneity (significance
level: P < 0.1). We will quantify the degree of heterogeneity using
the I² statistic (Deeks 2008). The guidelines for interpretation of
the I² values will be as follows.
• 0% to 40% indicates unimportant levels of heterogeneity
• 30% to 60% indicates moderate heterogeneity
• 50% to 90% indicates substantial heterogeneity
• 75% to 100% indicates considerable heterogeneity
We will also consider a visual inspection of the forest plot to iden-
tify whether CIs overlap.
Assessment of reporting biases
As we anticipate the inclusion of trials from the grey literature, it
is particularly important for us to conduct an assessment of publi-
cation bias. If we identify at least 10 trials for inclusion in a meta-
analysis, we will explore potential publication bias by generating
a funnel plot and performing Egger’s test to determine the degree
of asymmetry (Egger 1997). If the included trials differ in sample
size then we will visually inspect the funnel plots to explore the
possibility of reporting biases. The results of Egger’s test will also
be interpreted cautiously due to the presence of many limitations
in quantifying possible reporting biases (Moore 2008). We will
address the implications of the publication bias assessment on the
review findings in the discussion section.
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Data synthesis
We will synthesize the quantitative data compiled using the data
extraction forms using a meta-analysis. We will use continuous
data to calculate a MD or SMD for use in the meta-analysis, de-
pending on the scales of measurement used in the trials (according
to the reasoning in ’Measures of treatment effect’). We will calcu-
late the appropriatemeasure of association (e.g. RR) for estimation
of relative risk using categorical data. The summary measures will
be pooled as appropriate, according to the scales used in different
trials. We will calculate the I² statistic to determine statistical het-
erogeneity, and thus determine whether a fixed-effect model (neg-
ligible heterogeneity), or a random-effects model (non-negligible
heterogeneity) should be used for themeta-analysis (DerSimonian
1986). The results of the meta-analysis will be reported as pooled
effect estimates, stated with 95% CIs and illustrated graphically
in a forest plot.
If meta-analysis cannot be undertaken for a particular outcome
(due to an insufficient number of studies, or any other reason), we
will include reasoning for this, as well as a narrative discussion of
the available evidence relevant to the outcome variable in question.
Subgroup analysis and investigation of heterogeneity
If we identify substantial (or higher) statistical heterogeneity we
plan the following subgroup analysis investigating the possible
effect of TENS based on:
• age groups (below 18 years of age, 18 years and over);
• gender (male, female);
• stimulation parameters (e.g. high stimulation frequency
with low intensity, low frequency with a high stimulus intensity);
• frequency of administration of TENS (e.g. daily or not on a
daily basis);
• duration of treatment with TENS (e.g. 30-minute sessions
or more than 30 minutes).
Sensitivity analysis
We will assess the robustness of our findings by performing sen-
sitivity analyses according to Cochrane recommendations where
appropriate (Deeks 2011). If there are sufficient comparable tri-
als, i.e. 10 or more, we will perform sensitivity analyses to study
the effect of excluding trials with high risks of bias due to inade-
quate allocation of concealment, blinding, randomisation method
or level of dropouts. Furthermore, we will also consider the impact
of using a fixed-effect model compared to a random-effects model.
Summary of findings table
We will use the GRADE approach to create a ’Summary of find-
ings’ table, as suggested in chapters 11 and 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2011a; Schünemann 2011b). The table will present the trial pop-
ulation and setting, the type of intervention and control group, the
outcome measures listed below and an assessment of the evidence
quality (as measured by the GRADE approach).
We will use the GRADE approach to rate the quality of the ev-
idence as ’high’, ’moderate’, ’low’, or ’very low’ using the five
GRADE considerations.
1. Risk of bias: serious or very serious
2. Inconsistency: serious or very serious
3. Indirectness: serious or very serious
4. Imprecision: serious or very serious
5. Publication bias: likely or very likely
We will generate a separate ’Summary of findings’ table for each
comparison with the following outcomes:
• pain relief;
• pain intensity as assessed by VAS or any other validated
pain score;
• frequency of pain episodes;
• changes in consumption of analgesics and opioids during
pain episodes;
• changes in QoL (as measured by a validated scale);
• changes in ability to cope with the ADL;
• adverse effects of the intervention.
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A P P E N D I C E S
Appendix 1. Glossary
Term Definition
Afferent input Information from our sensory organs (e.g. eye, skin) transmitted as input to the central nervous system
(brain, spinal cord)
Avascular necrosis Cellular death of bone components due to interruption of the blood supply; the bone structures then collapse,
resulting in bone destruction, pain, and loss of joint function
Endogenous Originating or developing from within the body.
Haemolysis The destruction of red blood cells which leads to the release of hemoglobin from within the red blood cells
into the blood plasma
Hypersplenism A condition in which the spleen becomes increasingly active and then rapidly removes the blood cells
Neuropathic Due to disease of nerves.
Nociceptive Of, relating to, or denoting, pain arising from the stimulation of nerve cells (often as distinct from that
arising from damage or disease in the nerves themselves)
Non-invasive Not requiring the introduction of instruments into the body.
Pharmacogenomics The use of human genetic variations to optimise the discovery and development of drugs and the treatment
of patients
Presynaptic inhibition Refers to a decrease of transmitter release at central synapses
TIA Transient ischaemic attack caused by a temporary disruption in the blood supply to part of the brain
Appendix 2. Electronic searches
Database/ Resource Strategy
PubMed (1946 onwards) (sickle OR “Anemia, Sickle Cell”[Mesh]) AND (“Transcutaneous electric” OR “Transcutaneous
electrical” OR “Transcutaneous Electric Nerve Stimulation”[Mesh])
Embase (Ovid 1974 - to present) 1 exp Sickle Cell Anemia/
2 sickle.tw.
3 1 OR 2
4 Transcutaneous electric* nerv* stimulation.tw.
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(Continued)
5 TENS.tw.
6 Transcutaneous Electrical Nerve Stimulation/
7 (4 OR 5 OR 6)
8 (3 AND 7)
Clinicaltrials.gov [ADVANCED SEARCH]
STUDY TYPE: Interventional Studies
CONDITIONS: sickle
INTERVENTIONS: transcutaneous OR TENS
WHO ICTRP Two separate searches will be carried out:
SEARCH 1: sickle AND transcutaneous
SEARCH 2: sickle AND TENS
ISRCTN Registry [ADVANCED SEARCH]
CONDITION: sickle
INTERVENTIONS: transcutaneous OR TENS
Google Scholar sickle AND (“transcutaneous electric” OR “transcutaneous electrical” OR tens)
NOTE: The results will be sorted by “relevance” and the first 100 results screened for relevant
studies
Grey Literature Databases Two separate searches of each database will be carried out:
SEARCH 1: sickle AND transcutaneous
SEARCH 2: sickle AND TENS
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